BioSpace News Archive

Cayuga Biotech, an early-stage platform biotechnology company harnessing biomimetic polyphosphate to address severe bleeding and wound healing, announced that Andrea Ashford-Hicks has been named the company’s Chief Executive Officer.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the presentation of an e-Poster at the 2022 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress, which is being held virtually from March 7 – 8, 2022.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday, March 8, 2022 at 6:30 AM EST.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2021 financial results after market close on Wednesday, March 16, 2022.

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and other chronic neurodegenerative diseases, including Alzheimer’s in Down Syndrome (AD-DS).

MiNK Therapeutics, announced that it has begun dosing patients with solid tumor cancers with AgenT-797 alone and in combination with approved anti-PD-1 checkpoint inhibitors in a Phase 1 open-label clinical trial.

The Common Shares will be issued in reliance on certain prospectus exemptions available under Canadian securities legislation and will be subject to a four month and one day hold period from the date of issuance.

Albany NY, United States: The demand within the global market for surgical dental loupes and camera has been rising on account of advancements in the field of dentistry.

DUBAI, United Arab Emirates, Rising prevalence of chronic obstructive pulmonary disease and obstructive sleep apnea has been increasing the demand for respiratory devices.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the fourth quarter of 2021, and full year ending December 31, 2021.